Basal-type triple-negative breast cancers (TNBC) are aggressive and difficult to treat relative to luminal type breast cancers. TNBC often express abundant Met receptors and are enriched for transcriptional targets regulated by hypoxia inducible factor 1-alpha (HIF-1α), which independently predicts cancer relapse and increased risk of metastasis. 
͵

Introduction
Breast tumor kinase (Brk), also known as PTK6, is a soluble protein tyrosine kinase typically expressed in differentiated epithelial cells of the skin and gastrointestinal tract (1) . While Brk is not found in normal mammary tissue, it is aberrantly expressed in up to 86% of breast tumors, with the highest levels in advanced tumors (2) (3) (4) . Other cancers, such as melanoma, lymphoma, ovarian, prostate and colon cancer also exhibit overexpressed and/or mislocalized Brk (reviewed in (5)).
Brk contains N-terminal src homology 2 (SH2), src homology 3 (SH3) and C-terminal kinase domains. It is distantly related to Src family kinases, as they share 56% homology within the kinase domain (6) . Brk lacks a myristoylation site, and is present in both the cytoplasm and the nucleus. Many Brk substrates, both cytoplasmic and nuclear, have important functions in cancer, including signal transducer and activator of transcription (STAT) molecules, Akt, and Sam68 (reviewed in (5)). Brk is activated downstream of ErbB family receptors and Met receptors and is required for EGF-, heregulin-, and hepatocyte growth factor (HGF)-enhanced cell migration (7) (8) (9) . Although Brk and ErbB2 have distinct gene loci, they are coamplified in some breast cancers (10) . Brk expression in ErbB2-induced tumors correlates with shorter latency and resistance to the ErbB2 inhibitor, Lapatinib (10) . Moreover, elevation of Brk expression in breast cancer cells confers resistance to the EGFR-blocking antibody, cetuximab, by inhibiting EGFR degradation (11) . Brk also mediates anchorage-independent growth in breast cancer cells through modulation of the IGF receptor (12) . While significant advancements have been made toward understanding the mechanisms of Brk signaling (5), little is known about the regulation of Brk expression in breast cancers.
Hypoxia-inducible factors (HIFs) are the principal mediators of transcriptional responses to cellular hypoxia (13) . Hypoxia-inducible factors (HIF-1 and HIF-2) are heterodimers of two oxygen-regulated subunits, HIF-1α or HIF-2α and HIF-1β. HIF-1β is constitutively expressed, whereas HIFα subunits are continually degraded through the ubiquitin pathway under normal oxygen tensions (normoxia). In response to hypoxia, Ͷ HIFα subunits are stabilized and translocate to the nucleus, where they heterodimerize with HIF-1β. HIF transcription factors recognize a core hypoxia-response elements (HREs) within enhancer regions of target genes (14, 15) , and act as master regulators of many cellular functions relevant to cancer progression, including angiogenesis, glucose metabolism, and tumor growth and metastasis (13) . Indeed, HIF-1α is overexpressed in many human cancers (reviewed in (16) ), and over-expression in breast tumors predicts relapse and indicates a higher risk of metastasis (17) . HIF-1α levels are significantly higher in invasive and poorly differentiated breast cancers as compared to welldifferentiated cancers (18) (19) (20) . Specifically, increased levels of HIF-1α mRNA and the core hypoxic transcriptional response are associated with hormone receptor negative breast cancers (19, 21) .
Breast tumors lacking estrogen receptor (ER), progesterone receptor (PR) and HER2, termed triple negative breast cancers (TNBC), are typically more aggressive relative to ER/PR/HER2 positive tumors. TNBCs largely fall into the basal and claudin-low molecular subtypes and have a worse prognosis relative to luminal breast cancers (reviewed in (22) ), in part, because these patients are not candidates for targeted therapies that block ER and HER2. TNBC patients are treated with systemic chemotherapies that include cytoskeletal-or DNA-damaging agents, which can be effective, but fail to specifically target the unknown and presumably diverse molecular drivers of cancer metastasis. As Brk is aberrantly expressed in both luminal and TNBC subtypes, but is not found in the normal mammary tissue, it is an attractive candidate for selective targeting of invasive breast cancer cells.
Herein, we examined the mechanism of Brk induction in breast cancer, with focus on TNBC/basal-type breast cancers abundantly expressing both Met and HIF target genes.
We hypothesized that Brk, a known mediator of Met signaling and stress activated kinase pathways, is upregulated in response to cellular hypoxia, thereby promoting cancer cell survival, cell motility, and metastasis. ͷ
Materials and Methods
Cell culture. MDA-MB-231 cell lines were cultured in DMEM (HyClone Thermo Scientific) without pyruvate supplemented with 10% FBS (Gibco, Invitrogen) and 1% pen/strep. Stable knock-down of HIF1A, HIF2A or both genes in MDA-MB-231 cells was generated by transduction as previously described (see Supplemental Methods) (20) . MDA-MB-231 shMock, shHIF1A, and shHIF2A cells were supplemented with 4μg/mL puromycin, and shHIF1A/2A cells were supplemented with 8μg/mL puromycin, and 2mg/mL hygromycin and authenticated 4/11/13 by SoftGenetics LLC or DDC Medical and results compared to the ATCC STR database.
Cells were maintained in 5% CO 2 at 21% O 2 (normoxia, ambient air) or at 1-2% O 2 (hypoxia).
Cell proliferation assay. Proliferation was measured via MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay as previously described (23) . MDA-MB-231 cells were plated at 2.5 x 10 3 cells per well in 24-well plates.
Protein extraction. Patient-derived xenograft tissue fragments maintained by the HCI breast tumor bank resource (24) were obtained (Supplementary Table 1 ). High-salt enriched whole cell lysates (HS-WCE) were prepared from HCI tumors or MDA-MB-231 tumors as previously described (25) . Whole cell lysates from cultured cells were isolated as described in (26) .
Additional human tumor specimens were obtained from the University of Minnesota Biological Materials Procurement Network (BioNet) and histologically subtyped and processed for protein expression as previously reported (23) .
Immunoblotting. Proteins were resolved on 7.5% SDS-PAGE or 3-8% Tris-Acetate gels, 
Transgenic mice and generation of tumors in NOD/scid/gamma recipients
MMTV-PyMT+ HIF-1 wildtype (WT) and knockout (KO) mammary tumors were generated as described in (25) . WAP-Brk transgenic mice (4) and Met mutant knock-in mice were generated as described (27) , monitored daily for tumor development and euthanized when tumor volume and tumor volumes were calculated by caliper measurement as described previously (28) . At experimental endpoint, tumor wet weight was also measured.
Immunostaining:
Immunohistochemistry of HIF-1 WT and KO mammary formalin-fixed paraffin-embedded tumor sections was performed as previously described (4 
Statistical analysis:
Results are presented as means +/-SEM. Statistical significance for qPCR assays was determined using unpaired Student's t-tests. Tumor xenograft growth significance over time was determined via two-way ANOVA with Bonferroni correction. Tumor latency was analyzed using KaplanMeier methodology and curves compared using the Mantel-Cox Log-rank test. Brk mRNA levels
were assessed using the Cancer Genome Atlas (TCGA) data. The above results suggest that Brk induction may be characteristic of more universal responses to cellular stresses that also input to HIF-1α (31) . We therefore assessed the levels of Brk expression in response to increasing concentrations of reactive oxygen species (ROS) by treatment with hydrogen peroxide (H 2 O 2 ) and following glucose deprivation. When MDA-MB-231 cells were exposed to H 2 O 2 (0-100 ȝM), Brk and HIF-1α protein levels were induced or stabilized, respectively, in a dose dependent manner (Fig. 2D) . A similar response occurred when cells were exposed to media containing (Fig 2E) . These data, indicating Brk induction by multiple cell stress pathways, suggest a mechanism for coordinate regulation of downstream signaling in response to HIF activation.
Results
Brk is upregulated in response to
Brk is a novel, direct HIF transcriptional target gene.
The Brk promoter contains multiple potential hypoxia response elements (HREs) within 20 kb of the transcriptional start site (TSS) (Fig. 3A) . To examine HIF-α recruitment these regions, we performed chromatin-immunoprecipitation (ChIP) assays with MDA-MB-231 cells cultured at normoxia or hypoxia for 24 hours. We observed that HIF-1α and HIF-2α were robustly recruited to HRE 1 located 1.5 kb upstream of the Brk TSS at hypoxia compared to normoxia (Fig. 3B) . As a functional correlate of transcriptional activity associated with this HRE, we assessed the recruitment of RNA polymerase II to this region (HRE 1) and observed robust recruitment of this enzyme following exposure to hypoxia (Fig. 3B ). These data suggest that HIF-containing transcriptional complexes present at HRE 1 in hypoxia are active. Essentially identical results (i.e. hypoxiaregulated recruitment of HIF-1α, HIF-2α, and Pol II) were obtained for HREs 2-5 (Supp. (Fig. 4A) . These results were confirmed by immunofluorescence staining for Sik (red) and DAPI-nuclear staining (blue) (Fig. 4B) . Sik was localized in the tumor epithelium and stroma. A no primaryantibody control demonstrated that immunoreactivity was entirely due to the primary Sik (Fig. 4A) ; the specificity of Sik antisera was shown previously (34) .
Additionally, four HIF-1 WT and four HIF-1 KO PyMT tumors were assessed for Sik protein levels by Western blotting. We observed a marked reduction in Sik protein in HIF-1 KO tumors relative to HIF-1 WT tumors (Fig. 4C) . Therefore, HIF-1α is required for robust expression of Sik in PyMT-mouse mammary tumors.
Despite dramatic reduction in HIF-1 KO PyMT-tumors, Sik protein was still weakly detected (Fig. 4) . Notably, HIF-1α and HIF-2α have overlapping transcriptional targets (20, (35) (36) (37) . Therefore, we tested the dependence of Brk expression on HIFα molecules in human breast cancer cells cultured under hypoxic conditions. MDA-MB-231 cells expressing empty vector (shControl), HIF1A shRNA, HIF2A shRNA, or both HIF1A and HIF2A shRNAs (DKD) were cultured at normoxia or 1% O 2 for 6 or 24 hours. As expected, HIF-1α and HIF-2α protein levels were increased at 6 and 24 hours in shControl cells cultured at hypoxia; target gene expression was greatly reduced in hypoxic shHIF1A and shHIF2A cells (Fig. 5A ). We observed a substantial hypoxiainduced increase in HIF-2α protein expression in cells expressing shHIF1A relative to shControls. The up-regulation of HIF-2α in response to efficient HIF1A knockdown was previously shown in MCF-7 cells (20) . Importantly, only double-knock down (DKD) cells completely lacked both HIF molecules (Fig. 5A) . Brk mRNA was significantly decreased in MDA-MB-231 cells expressing either shHIF1A or shHIF2A relative to shControl cells, but significantly induced by hypoxia relative to normoxia (Fig. 5B) .
However, when both HIF1A and HIF2A were simultaneously knocked down, we observed an almost complete ablation of Brk transcript and protein expression (Fig. 5B   inset) . Similar results were observed in MCF7 cells (Supp. Fig. 1C ). These data suggest that when expression of either HIF-1α or HIF-2α is lost, the other HIFα subunit may . 3A) , and the cells were thus unable to induce endogenous Brk (Supp. Fig. 3B ). In contrast, DKD cells engineered to over-express wildtype BRK exhibited constitutive Brk expression, as expected (Supp. (Fig. 6A ).
These cells (shControl, DKD and DKD + Brk) were used to establish orthotopic mammary tumors in NOD scid gamma female recipients (n=9 mice/cohort). Xenografts were palpated and tumor growth was measured with digital calipers as previously described (28) . In agreement with previous reports (38-40), knockdown of both HIF1A and HIF2A significantly decreased breast cancer cell growth in vivo relative to shControl cells at day 38; 780.6 ± 98.4 mm 3 vs. 558.0 ± 36.0 mm 3 , respectively ( Fig. 6B-C) . (24) (Fig 6D) . These data suggest that in vivo, Brk is a major driver of breast cancer phenotypes that are typically associated with HIF-1α/2α mediated tumor progression and metastasis.
Brk increases the appearance of basal-like mammary tumors in MET mut mice.
Our recent work demonstrated that Brk signals downstream of Met receptors to increase
HGF-driven malignant processes in vitro (8) . High Met receptor levels are also strongly correlated with TNBC and basal-like breast cancers (27) . Therefore, we sought to (Fig. 7C) . Mice with Sik-positive tumors had a median survival of 221 days, whereas mice with Sik-negative tumors had a median survival of 397.5 days. Overall, the decreased latency correlated with significantly higher levels of Sik in tumors (Fig. 7C-D) ,
suggesting that Sik expression accelerates tumor development and progression.
To further support these findings as relevant to human tumors, we stratified 117 primary human breast tumor samples according to Brk mRNA expression (42). High Brk expression correlated significantly with both decreased overall survival (Fig. 7E ) and decreased metastasis-free survival (Fig. 7F) . These data suggest that the WAP-Brk x MET Mut mice model human disease with high Brk expression. These mice may provide a 
ͳͶ useful model system for pre-clinical testing of novel therapies that may include Brk inhibitors.
DISCUSSION
Although an improved understanding of Brk signaling in breast cancer is emerging (5, 7-9), knowledge of the mechanisms by which Brk is aberrantly expressed in the majority of breast cancers remains incomplete. We have identified cellular microenvironmental stressors, including hypoxia, to be major cues that result in increased Brk expression in both normal and neoplastic mammary epithelial cells. We have additionally shown through ChIP assays and gene expression analysis that this mechanism of Brk transcriptional regulation is HIF-dependent. This finding is particularly relevant to breast cancer subtypes that exhibit high constitutive expression of HIFα subunits, specifically, TNBCs ( Fig. 1) and inflammatory breast cancers (19, 21) . Importantly, forced expression (Fig. 7E-F) . Further studies, designed specifically to assess differences in metastases (i.e. following removal of primary tumors and/or using larger cohorts (43)), are needed to better define the details of how Brk signaling contributes to the stepwise process of metastasis. 
ͳͷ
Our data suggest that Brk can be up-regulated during hypoxia by either HIF-1 or HIF-2 (Fig. 5) . Numerous studies have determined that HIF-1α and HIF-2α regulate several of the same genes (20, 35, 36) , as expected since the core binding sequence (RCGTG) is recognized by both HIF-1 and HIF-2 (37, 44) . Indeed, significant levels of both HIF-1α and HIF-2α have been observed to bind to almost all of the HIF binding sites identified by ChIP genome wide. However, functional analysis of the role of individual HREs in the regulation of Brk expression by HIFs is outside the scope of this study. Genome-wide studies have also shown that, despite sharing the same response element, each HIFα subunit also differentially regulates a unique core of distinct genes (37) . These studies highlight the complexity of HIF gene regulation and the possibility that HIF-1α and HIF-2α may be involved in both cooperative and compensatory gene regulation that is highly context-dependent (20) , and underscore the need for further study. Molecular compensation (i.e. of one HIF for another) is an important consideration for targeting HIF-specific actions in the clinic.
Solid tumors experience widespread cell stress that acts as a form of selection pressure. Our previous studies have elucidated downstream mediators of Brk signaling that include stress-activated protein kinases (p38 MAPK and ERK5) and their substrates MEF2 and Sam68 (7) (8) (9) . Intriguingly, in hTERT-RPE1 cells, HIF-1 transcriptional activity was enhanced by ERK5, and numerous hypoxia-regulated and HIF-1α target genes were specifically regulated by ERK5 (45) . These results suggest that HGF, Met, Brk, ERK5, and HIF-1α may function together as a "feed-forward" autocrine signaling loop in response to hypoxia, ultimately resulting in high levels of Brk expression and adaptation to cell stress that enables cancer cells to migrate away from hypoxic regions to more hospitable microenvironments at distant sites. Related to this process is the epithelial to mesenchymal transition (EMT), a quintessential step that precedes carcinoma cell metastasis (46) . HIF-1 is known to mediate EMT in breast tumors (25) and knock-down of Brk in MCF7 breast cancer cells partially reverses EMT, as measured by a decrease in mesenchymal markers (fibronectin and N-cadherin) and an increase in epithelial markers (E-cadherin and β-catenin) (47) . Taken together, these studies suggest that increased Brk expression allows breast cancer cells to successfully migrate, in part 
